You are now leaving Alnylam.com. We are advancing a robust pipeline of innovative RNAi-based medicines in four therapeutic areas: genetic medicines, cardio-metabolic diseases, infectious diseases, and central nervous system (CNS) and ocular diseases.The following content may not be associated with Alnylam Pharmaceuticals. Alnylam welcomes you to Capella, the destination for updates on our progress in translating the science of RNAi into innovative medicines. Alnylam Pharmaceuticals does not endorse and is not responsible for the content on sites that are not owned and operated by Alnylam Pharmaceuticals.We are hosting a series of online “RNAi Roundtables” at which Alnylam scientists and program leaders, as well as clinical collaborators, will review recent progress in many of our pipeline programs and platform. If you’re having trouble finding something specific please send an inquiry to investors@alnylam.com: Mar 24, 2020 Receive news and updates on the work at Alnylam that affects you most.To those who say “impossible, impractical, unrealistic,” we say:We are focused on diseases for which treatment options are limited or simply don't exist.Patients are at the core of everything we do. Alnylam Pharmaceuticals does not endorse and is not responsible for the content on sites that are not owned and operated by Alnylam Pharmaceuticals. The following content may not be associated with Alnylam Pharmaceuticals.
Links to all outside sites are provided as a reference for our visitors.
For Alnylam, Capella is our online voice for communicating the scientific progress we are making as we work to develop innovative medicines for patients.New positive results from an interim analysis of the Phase 2 open-label extension (OLE) study of fitusiran, in development for the treatment of hemophilia A or B, with or without inhibitors, were presented at the World Federation of Hemophilia (WFH) Virtual Summit, held June 14-19, 2020.An abstract describing new 12-month interim data from the ongoing ENVISION open-label extension (OLE) study of givosiran in patients with acute hepatic porphyria (AHP) has been published online by the European Association for the Society of the Liver (EASL) on the International Liver Congress™ (ILC 2020) website. Proceed to Site Learn about Alnylam Pharmaceuticals, RNAi therapeutics, and the company's efforts in treating amyloidosis, hyperoxaluria, and porphyria. In 2018, our first medicine, ONPATTRO® (patisiran), became the world’s first approved RNAi therapeutic. On July 17, 2020, we hosted an online RNAi Roundtable to review progress in our early stage RNAi therapeutics pipeline.Receive news and updates on the work at Alnylam that affects you most.New results and analyses of study data for ONPATTRO® (patisiran) were presented at the 2020 Peripheral Nerve Society (PNS) Annual Meeting, held June 27-30 as a virtual event.Positive results from the ILLUMINATE-A Phase 3 study of lumasiran, an investigational RNAi therapeutic in development for the treatment of Primary Hyperoxaluria Type 1 (PH1), were presented by study investigators at the European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) International Congress, held June 6-9, 2020 as a virtual event.Alnylam welcomes you to Capella, the destination for updates on our progress in translating the science of RNAi into innovative medicines. Our second medicine, GIVLAARI® (givosiran), was approved by the FDA in 2019. Find the latest Alnylam Pharmaceuticals, Inc. (ALNY) stock price as well as historical stock price data. Learn about Alnylam Pharmaceuticals, RNAi therapeutics, and the company's efforts in treating amyloidosis, hyperoxaluria, and porphyria. For Alnylam, Capella is our online voice for communicating the scientific progress we are making as we work to develop innovative medicines for patients. Our Pipeline Clinical Trials Medical ... Alnylam Pharmaceuticals does not endorse and is not responsible for the content on sites that are not owned and operated by Alnylam Pharmaceuticals.
We’re seeking smart, passionate, “change the world” kind of people who are ready to say, “challenge accepted” to our mission.Learn more about our investigational therapies across multiple disease areas.
.
造反 騎手 誰, アクター 意味 政治, カリフォルニアディズニー カチューシャ 名前, ヤクルト 杉浦亨 現在, ヨルシカ 夢の中へ ダウンロード, 人魚の眠る家 キャスト 榎田, 盛岡 愛知 新幹線, Ego 和訳 Willy, ヴィッセル神戸 ユニフォーム 安い, 高校野球 予選 試合数, 次世代AK ハンドガード 交換, ゼクシィ カウンター 千葉, Thanks Though 意味, ドローン 飛ばせる場所 神戸, しにせ の ゲーム 実況, ガス ライフル AK, ドラクエ10 アモデウス 転生, 風営法 施行規則 パチンコ, パワプロ 2019 六道, 婚約指輪なし 結婚指輪 割り勘, 好きな女 結婚 辛い, ゼクシィ縁結び マッチングしない 男性, 骨 塩 定量 検査 Bml, 雨樋 メーカー シェア, ドラクエ10 職業の証 再入手, 金銀 旅パ 最強, 靴磨き 布 巻き方, セレビィ 色違い ポケモンgo, 金 八 先生 第5シリーズ 裏話, Atomic Heart Co-op, スティーブ ジョブズ 大学中退, Nordic Nest Marimekko, まごころを君に アスカ 腕, 夏 ノスタルジック 漫画, 一目ゴム編み 作り目 偶数, タナカ M40a1 カートリッジ, 重岡大毅 彼女 バー, ミスターミニット 池袋 クーポン, ブランド ストール クリーニング, そばかす レーザー 経過, 刑事と 検事 最終回 ゲスト, 切手買取 札幌 バイセル, ダンロップ モータースポーツ スニーカー, による けど 英語, Hulu アカウントページ お支払い, アルザ 泉大津 イベント, 京都大学 大学院 生命科学研究科 対策, ハードオフ ガスガン 買取, 矢作萌夏 す ち, 中日 開幕投手 歴代, 韓国 芸能界 性, Drs チャージ 加算, Dear Cloud ナイン インスタ, 高校入試 ドラマ 相関図, 自衛隊 依願退職 退職金 いつ, たかせ 瓦そば 通販, どなた に 御用 ですか, 三本の矢 本当 の意味, 山陽新幹線 九州新幹線 乗り継ぎ, シシドカフカ ショート パーマ, ニット 洗濯ネット おすすめ, M4 内部カスタム レシピ, 今江 敏晃 いんす た, とある魔術の禁書目録 幻想収束 クエスト, タスクキル PC コマンド, ロベルトカヴァリ 時計 口コミ, Akb48 また会える日まで Mp3, D006-4 遺伝学的検査 施設基準, ビタブリッド レベルアップ 解約, 胃 ニッシェ がん, 風の 通り道 パクリ, 聖書協会 共同訳 著作権, アクリル 毛玉 防止, Wanima ともに Pv ロケ地, 藍 色 ロシア語, 大学 廃 学,